Mirati Therapeutics competitors

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.

Biotech entrepreneur experienced in building small and large organizations, recruiting and inspiring teams, managing large global organizations, and raising money. Experienced in business development, corporate partnerships, acquisitions and mergers, and corporate governance. Board certified medical oncologist with 25 years’ experience in cancer research from basic laboratory research to drug approval. I have been in the pharmaceutical industry in clinical R&D, project leadership, business development and medical affairs for more than 20 years, with successful global registrations in breast cancer, non-small cell lung cancer and pancreatic cancer. Grew Abraxane to $1B product. Responsibility included drug launches and post-marketing medical strategy for Celgene's hematology/oncology pipeline, including Revlimid, Pomalyst/Imnovid and Abraxane. Led Cyteir from discovery company to clinical stage company.

David Arthur is a Chief Executive Officer at SALARIUS PHARMACEUTICALS, INC. and Board Member at SALARIUS PHARMACEUTICALS, INC. and is based in Wilton, Connecticut. He has worked as Managing Director at Dacon Pharma LLC, Process Improvement Engineer and Production Manager at Milliken & Co, and Business Development RTP N.C. at GSK. David studied at Fuqua School of Business between 1988 and 1990 and NC State University between 1980 and 1984.

Dr. James Breitmeyer is the president & CEO Oncternal Therapeutics, Inc., a San Diego cancer biotechnology company. He was instrumental in identifying and acquiring rights to ROR1 technology from UCSD and for developing ETS-family inhibitors based on discoveries from Georgetown University, while assembling Oncternal’s pipeline of oncology therapeutics. Dr. Breitmeyer was a lead author on the research grant submitted to the California Institute for Regenerative Medicine (CIRM) which resulted in the award of $18.3 million to UCSD to support development of lead program cirmtuzumab currently in Phase 1/2 clinical studies. Dr. Breitmeyer believes biomedical research and collaborations with academia are essential for targeting cancers where there are patients with critical unmet needs that aren’t being fully addressed by currently available therapies. At Oncternal, Dr. Breitmeyer is combining drug development expertise with exciting science for a synergistic combination to spur the development of novel product candidates that can potentially be applied across a large number of cancers. Dr. Breitmeyer is board certified in internal medicine and oncology. He holds a bachelor’s degree in chemistry from the University of California and earned M.D. and Ph.D. degrees from Washington University School of Medicine with fellowships at Washington University and Harvard Medical School. He held clinical and teaching faculty positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer has more than 30 years of experience across all aspects of the biotechnology industry in both large and small companies, and across multiple therapeutic areas. He is currently a member of the Boards of Directors of Oncternal Therapeutics Inc, Zogenix Inc, and Otonomy Inc.